AscellaHealth
Offering Comprehensive and Proactive Strategies to Specialty Pharmacy

However, the industry often presents a multitude of challenges for stakeholders involved in bringing innovative treatments to patients.

Through its comprehensive approach and proactive strategies within the specialty pharmacy ecosystem, AscellaHealth is at the forefront of solving these challenges.

The company ensures that it engages with manufacturers early in the drug development process to provide valuable insights and consultative services. Its proactive approach enables manufacturers to anticipate payer reactions, optimize clinical trial designs and strategize market entry plans.

Ensuring Efficient Product Access and Delivery
By offering a range of support services, including patient access, drug fulfillment and copay assistance programs, AscellaHealth prioritizes the patient experience. The company starts by understanding the patient journey and proactively addressing barriers to access. This ensures that patients receive timely and comprehensive care. Next, AscellaHealth collaborates with manufacturers to negotiate favorable reimbursement contracts by leveraging its expertise in payer dynamics. This includes navigating copayment assistance programs, optimizing pricing strategies and advocating for patient access. The company optimizes distribution processes to ensure efficient product access and delivery. By establishing robust supply chain networks and implementing inventory management solutions, AscellaHealth minimizes disruptions and maximizes product availability.

What assists AscellaHealth is its deep understanding of regulatory requirements. This enables the company to help manufacturers in navigating compliance challenges. From clinical trial management to post-approval monitoring, it provides guidance to ensure regulatory adherence.

“We are recognized as a trailblazer in ushering groundbreaking therapies, with global end-to-end solutions for life science manufacturers that span the entire product lifecycle,” says Dea Belazi, the CEO of AscellaHealth. “As the sole provider for product commercialization of specialty medications and advanced cell and gene therapies aimed at treating patients with rare or complex chronic diseases, our role encompasses addressing the diverse array of challenges encountered by manufacturers.”

AscellaHealth’s comprehensive portfolio of novel, innovative services and programs supports product launch and commercialization, including pre-commercialization and market access strategies, exclusive distribution, international fulfillment, outcomes tracking data and analytics.

Drawing upon the strategic expertise and deep experience of its professionals in managing rare and complex diseases, AscellaHealth positions itself as an indispensable, collaborative partner for manufacturers navigating the complex specialty market landscape.
The company’s approach extends beyond logistics, incorporating financial solutions to ease payment burdens for payers and raise the confidence level of manufacturers that their products will be reimbursed. Additionally, patient-centric initiatives, including copay assistance programs, further ensure successful product launches, patient compliance with treatment and sustained accessibility for individuals who need these potentially lifesaving treatments.

We are recognized as a trailblazer in ushering groundbreaking therapies, with global end-to-end solutions for life science manufacturers that span the entire product lifecycle

AscellaHealth's commitment to payers is embedded in customizable services, accompanied by extensive specialty pharmacy and rare disease expertise that drives innovative cost-containment strategies and solutions. These innovative end-to-end solutions are designed to control specialty drug spend without compromising the quality of care for patients, as well as customized clinical programs for enhanced member outcomes.
Recognized for a collaborative approach and strategic alliances designed to support payers in their opportunities for product reimbursement, AscellaHealth brings potentially lifesaving therapies to health plan members. By empowering payers with actionable data, streamlined processes and innovative programs—from addressing reimbursement challenges to optimizing financial platforms—AscellaHealth stands as a dedicated partner committed to enhancing member access, reducing costs, optimizing clinical outcomes and ensuring the overall efficiency of payer operations.

“Our portfolio of customizable programs, accompanied by extensive specialty pharmacy and rare disease expertise, addresses the unmet needs of partners, including payers,” says Belazi.

Creating Program Optimization and Success

What separates AscellaHealth is its team of dedicated patient care coordinators (PCCs). They provide a human touch, with tech-enabled support at every stage of the journey that guides patients and families to take advantage of these opportunities and adhere to treatment and care recommendations. Its team comprises experts who have decades of expertise in delivering innovative solutions that result in enhanced outcomes for rare disease patients and individuals with chronic, complex conditions.

By seamlessly integrating personalized support, innovative financial services, and a dedicated focus on data collection, AscellaHealth offers tailored solutions that optimize programs, drive success for clients and enhance outcomes for patients. Offering end-to-end services helps clients understand how different segments of the journey are connected, and as a key strategic partner, AscellaHealth leads clients through the process, ensuring all milestones are successfully completed.
AscellaHealth’s culture is one of diversity and inclusion with a patient-centric approach in everything it does. The company emphasizes growth and recruits new talent with unique specialty pharmacy and healthcare expertise, supporting its core mission to improve health outcomes and optimize the journey for patients with rare diseases as well as chronic or complex conditions.

“We know that a diverse team is a competitive advantage. AscellaHealth’s leadership team leads our almost 300 employees by example, demonstrating values of innovation, technology and passion to better the lives of the rare disease patients,” says Belazi.

Standing at the Cusp of the Promise of Meaningful Treatments

Looking ahead, AscellaHealth is eager to expand its programs across the U.S., U.K., and Europe to meet the growing demand for specialized care among patients. This expansion is particularly crucial given the ongoing development and approval of new, often costly therapies. The promise of meaningful treatments and potentially a cure for some of the most devastating and rare genetic diseases—such as hemophilia, rare cancers, sickle cell anemia and Duchenne's muscular dystrophy—is bringing hope to millions of people worldwide. In the early 1980s, there were less than 40 medicines available to treat these conditions, which collectively afflict roughly 30 million people in the U.S.

Now, the FDA has approved more than 880 drugs—almost half in the past decade. Another 700 potential treatments are under development. With the global Cell and Gene Therapy market expanding at an unprecedented pace and the FDA poised to approve an estimated 13 new CGTs in the U.S., Europe or both, the necessity for innovative patient-facing engagement solutions is becoming increasingly critical. AscellaHealth is all prepared to ride this wave.